Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JS004 + toripalimab + bevacizumab as first-line therapy for advanced hepatocellular carcinoma
ChiCTR2400092774Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tifcemalimab, toripalimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
tifcemalimabtoripalimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400092774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092774.